The secondary outcomes are depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment, adverse events, and withdrawal of trial medication due to adverse effects.
Study Will Evaluate Bipolar Medication in Treating Borderline Personality Disorder
Aug 12, 2015 | Bill Schu
Borderline personality disorder (BPD) is challenging to diagnose and treat. As yet, there are no drugs currently licensed for BPD treatment. In fact, guidance from England’s National Institute for Health and Care Excellence recommends that pharmacologic therapy not be used for patients with BPD at all. This is potentially troubling, because those patients typically experience rapid and extreme changes in mood, poor social functioning and have high rates of suicidal behavior.
Some smaller-scale research has suggested that mood stabilizers may produce short-term reductions in symptoms of BPD, but few controlled, randomized clinical trials have been undertaken in this area. A new study announced in Trials will compare the effectiveness of the bipolar disorder and anti-seizure medication lamotrigine, which has been shown to be effective at preventing or delaying some depressive effects in patients with bipolar disorder, versus placebo in patients with BPD.
The lamotrigine and borderline personality disorder: Investigating Long-term Effectiveness trial (LABILE) is a multi-center, two-arm, parallel group, double-blind, placebo-controlled randomized trial with three-, six-, and 12-month follow-up assessment. It will be the first study to examine the long-term clinical effectiveness and cost-effectiveness of lamotrigine for people with BPD.